MBRX Moleculin Biotech Inc
Company Analysis
Latest News
🔴 Moleculin Biotech is trading 5.7% down today following a discounted $9.3 million public offering
Moleculin Biotech is trading at $0.40 (-5.69%) in pre-market following a sharp post-offering selloff triggered by a discounted $9.3 million public offering. •...
🔴 Moleculin Biotech is trading 10.2% down today amid post-offering volatility and dilution worries
Moleculin Biotech is trading at $0.38 (10.2% down) following a sharp pullback in thin after-hours trading. • The decline extends a multi-day selloff...
🔴 Moleculin Biotech is trading 6.2% down today as post-offering volatility and dilution concerns persist
Moleculin Biotech is trading at $0.40 (6.2% down) in after-hours sessions, extending volatility following its recent $9.3 million discounted public...
🟢 Moleculin Biotech is trading 5.4% up today as shares stabilize after a $9.3M public offering selloff
Moleculin Biotech is trading at $0.42 (5.4%) up today as the stock stabilizes following a sharp multi-day selloff triggered by a deeply discounted $9.3 million...
🔴 Moleculin Biotech is trading 35% down today after pricing $9.3M public offering at a steep discount
Moleculin Biotech is trading 35% down at $0.29 after pricing a $9.3 million public offering at a steep discount to recent market levels. • The offering,...
🔴 Moleculin Biotech Plunges 21.6% After Pricing $9.3 Million Public Offering at $0.75 Per Share, Despite Positive Interim Trial Data
Moleculin Biotech is trading 21.6% down at $0.80 today, extending a sharp multi-day slide. • The company announced the pricing of a $9.3 million public...
Moleculin Reports Positive Interim Data from MIRACLE AML Trial, Showing 37% Remission Rate
Moleculin Biotech announced updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin for treating relapsed or...
Moleculin's Leukemia Drug Showed Promise — So Why Is the Stock in Freefall, and Can This Company Survive Long Enough to Benefit?
Shares of Moleculin Biotech cratered 60% in four trading days, sliding from $2.19 to $0.86, after the company filed a new registration statement to sell shares...
🔴 Moleculin Biotech is trading 15.6% down today as it extends a multi-day slide amid cash runway and clinical trial concerns
Moleculin Biotech is trading 15.6% down today at $0.86 as the stock extends a sharp multi-day slide amid investor focus on its cash runway and clinical trial...
🟢 Moleculin Biotech is trading 17.6% up today as it rebounds from a sharp multi-day selloff
Moleculin Biotech is trading 17.6% up at $1.20 in pre-market action, rebounding after two sessions of steep losses that drove shares from $2.19 down to...
🟢 Moleculin Biotech is trading 6.5% up today as it stabilizes after a heavy selloff
Moleculin Biotech is trading 6.5% up at $1.09 in pre-market action, showing signs of stabilization following two days of heavy losses. • The stock recently...
🔴 Moleculin Biotech is trading 10.3% down today on follow-through pressure after yesterday's sharp drop
Moleculin Biotech is trading at $1.24 (10.3% down) as the stock continues to face selling pressure following a significant decline in the previous session. •...
🔴 Moleculin Biotech is trading 14.8% down today on heavy early-session weakness with no fresh news
Moleculin Biotech is trading 14.8% down at $1.86 on heavy early-session weakness, despite no fresh company-specific news being identified so far. • The...
🟢 Moleculin Biotech is trading 6.6% up today amid a broader biotech sector rally
Moleculin Biotech is trading at $2.26 (+6.60%) following a strong intraday rebound, despite a lack of company-specific news, earnings, or FDA catalysts. The...
🔴 Moleculin Biotech is trading 5.5% down today amid broader biotech weakness and 52-week lows
Moleculin Biotech is trading 5.5% down at $2.18 today, extending recent weakness as the stock hits a new 52-week low amid broader market risk-off sentiment. •...
🔴 Moleculin Biotech is trading 5.7% down today amid profit-taking after recent gains
Moleculin Biotech is trading 5.7% down at $2.30, giving back a portion of its recent gains following a strong upward move that began in late June. • The...
🔴 Moleculin Biotech Inc is trading 5.11% down in pre-market
MBRX is trading at $2.20, down 5.11% in pre-market.
🔴 MBRX is trading 5% down today after disappointing trial results and Q1 earnings miss
MBRX is trading 5% down at $2.28 as investors react to disappointing interim cancer trial results and a significant Q1 2026 earnings miss. • The stock has...
🔴 MBRX is trading 5% down today after disappointing trial data and earnings miss
MBRX is trading 5% down at $2.51 in pre-market, extending a multi-day slide following disappointing interim cancer trial data and a sizable Q1 2026 earnings...
🔴 MBRX is trading 6.7% down today following disappointing interim clinical trial data
MBRX is trading 6.7% down at $2.51 today, as investor sentiment continues to be impacted by recent interim clinical trial data. • On June 30, 2026, Moleculin...